Categories: HealthcareNews

Oscar Health to Present at Upcoming Healthcare Conferences

NEW YORK–(BUSINESS WIRE)–Oscar Health, Inc. (“Oscar”) (NYSE: OSCR), a leading healthcare technology company, today announced its leaders will present and provide a business update at three upcoming healthcare conferences:


  • 2024 Wells Fargo Healthcare Conference: Chief Financial Officer, Scott Blackley, will participate in a fireside chat at approximately 12:45 p.m. ET on September 4, 2024.
  • Morgan Stanley 22nd Annual Global Healthcare Conference: Chief Executive Officer, Mark Bertolini, will participate in a fireside chat at approximately 1:50 p.m. ET on September 5, 2024.
  • Baird 2024 Global Healthcare Conference: Chief Financial Officer, Scott Blackley, will participate in a fireside chat at approximately 2:35 p.m. ET on September 11, 2024.

All interested parties are invited to listen to a live webcast by visiting ir.hioscar.com and selecting the “Events & Presentations” link. Following each presentation, a webcast replay will be available on Oscar’s investor relations website for 90 days.

About Oscar Health

Oscar Health, Inc. (“Oscar”) is a leading healthcare technology company built around a full stack technology platform and a relentless focus on serving our members. We have been challenging the status quo in the healthcare system since our founding in 2012, and are dedicated to making a healthier life accessible and affordable for all. Oscar offers Individual & Family plans and health technology solutions that power the healthcare industry through +Oscar. Our technology drives superior experiences, deep engagement, and high-value clinical care, earning us the trust of approximately 1.6 million members, as of June 30, 2024.

For more information, please visit www.hioscar.com.

Contacts

INVESTOR RELATIONS:
Chris Potochar

ir@hioscar.com

MEDIA RELATIONS:
Kristen Prestano

press@hioscar.com

Staff

Recent Posts

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…

1 hour ago

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…

1 hour ago